We engineer "attack particles" that selectively target and kill cancer cells, eliminating unwanted side effects and toxicity.
Tl;dr: We are Granza Bio, two PhD graduates in Oncology and Immunology from the University of Oxford on a mission to develop personalised and targeted cancer treatments. We are working on a new weapon in our immune system’s arsenal – “attack particles”. We are turning this concept into a therapeutic product that can eliminate any cancer without harming the surrounding healthy cells, preventing adverse side effects.
Hey everyone, we are (Ashwin)²
🧑🏾Ashwin Jainarayanan – Clarendon Scholar and Synthetic Immunologist with extensive research experience on attack particles derived from immune cells.
🧑🏾Ashwin Nandakumar – Cancer biologist specializing in immuno-oncology, who has previously set up clinical trials and brings extensive Oncology start-up experience.
👨🏻🔬 Mike Dustin – Professor of Molecular Immunology at the University of Oxford. Widely recognised for his work on immunological synapses and discovered attack particles.
~50% of cancer patients receive treatments that are (1) ineffective and (2) lead to unwanted and avoidable side effects.
(1) High mortality rates: Ineffective treatments lead to cancer relapse and ultimately, increased likelihood of dying from cancer. Five-year survival rates are lower than 5% for patients with late-stage cancers including lung, pancreas, and brain cancer.
(2) Toxicity and adverse side effects: While emerging treatments such as immunotherapy and CAR-T cell therapy are effective in some patients, they also impact their healthy tissues. This causes high toxicity and adverse side effects.
We have identified attack particles ⚡: a powerful suite of weapons in our immune system’s arsenal. These attack particles carry proteins like granzymes and perforins that instantly kill cancer cells.
Lock & Key method – attack particle targeting cancer